HERANTIS PHARMA

Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need

MAY 2024

Herantis in Brief

Herantis Pharma plc was **founded in Helsinki, Finland in 2008; Listed** at Nasdaq First North Helsinki

Developing disease-modifying treatment to address the unmet clinical need in Parkinson's disease and other neurodegenerative diseases

Lead asset **HER-096** is a small engineered peptide molecule with a **unique mechanism of action** and **subcutaneous injection** as an **easy route of administration**

Phase 1a clinical trial readout in October 2023: Good safety profile, blood-brain barrier (BBB) penetration demonstrated

Ambition: engage with a partner before Phase 2

The unmet clinical need in Parkinson's disease

PARKINSON'S DISEASE (PD)

- Degeneration of dopaminergic nerve cells in mid brain results in loss of dopamine that cause severe motor and non-motor symptoms
- At the time of diagnosis, approximately half of the dopaminergic activity is lost



CURRENT TREATMENTS CANNOT STOP THE PROGRESSION OF PD

- For 50 years, the mainstay of Parkinson's treatment has been levodopa, which helps to restore dopamine levels in the brain

BLOOD-BRAIN BARRIER (BBB) PROTECTS THE BRAIN

- Most pharmaceuticals cannot pass the BBB
- Efficient BBB penetration is important reach the target tissue within the brain



UNMET NEED: DISEASE-MODIFYING TREATMENTS

HERANTIS' HER-096

- **Efficient BBB-penetration**
- **HER-096 Slows down or stops the progression of Parkinson's disease**

OVER $10B MARKET

- 8-10 million patients globally
- Current market $5B
- Market estimated to grow to $11B by 2029 driven by disease-modifying treatments (source: GlobalData)

HER-096 restores the normal function of the dopaminergic neurons



Preclinical | HER-096 Improves Motor Function in Mouse PD Model (α-Synuclein Fibril Model)



CLICK THE BELOW LINK TO SEE THE VIDEO:

https://youtu.be/L3WmkhP2Opw

Status of HER-096 Program

- Clinical
  - Phase 1a completed in 2023 (single ascending dose in healthy volunteers) ➔ data support moving forward with subcutaneous HER-096 dosing
  - Phase 1b in PD patients planned to be started in 2H 2024 (4 weeks treatment for safety and tolerability, biomarkers)
- Preclinical
  - Strong preclinical efficacy data demonstrating the MoA (α-synuclein fibril model)
  - 28-day daily dosing GLP toxicology study completed
  - 6-month toxicology study planned to start in late 2024
- Manufacturing
  - HER-096 bulk manufactured by solid phase peptide synthesis (SPPS) by Bachem AG (Switzerland), current scale 1000 grams, straightforward further scale-up
  - Phase 1b GMP manufacturing ongoing
  - Formulation development work on-going to decrease the volume of injection for Phase 2
- IPR
  - Composition of matter patent filed in Dec 2019 (WO2021123050A1)

Recent Business highlights

- HER-096 Phase 1a clinical trial met all primary and secondary endpoints
  - Favorable safety and tolerability profile
  - Fast uptake of HER-096
  - Significant HER-096 concentration in the cerebrospinal fluid (CSF) after a single subcutaneous injection
- Funding/financing
  - €2.5 million grant funding from the EIC Accelerator program over the next two years secured in April 2023.
  - Direct equity investment term sheet from EIC Fund of up to €15 million signed in July 2023. EIC to participate with maximum of 1/3 of the future share issues.
  - Successfully completion of a directed share issue raising gross €4.5 million in December 2023.

Seeking a partner for HER-096 to co-develop future potential

Preclinical and clinical expertise with the same mechanism of action with CDNF protein

HER-096 global patenting

Straightforward manufacturing

Preclinical evidence of disease modifying effect

HER-096 is delivered to the human brain after subcutaneous administration

Significant opportunities in further development in Parkinson's and in other neurodegenerative diseases

Summary

What we want to achieve with HER-096?

To develop a treatment to slow or stop the progression of Parkinson's disease with symptomatic relief

Evidence of subcutaneous HER-096

- HER-096 is delivered in the central nervous system in humans in therapeutic concentrations
- Good safety and tolerability profile in humans
- Strong preclinical efficacy data in aged mouse model of Parkinson's disease (α-synuclein model)
- **Clinical and preclinical experience and evidence with CDNF protein in Parkinson's disease that has the same MoA as HER-096**

Next steps

- Phase 1b to start in 2024 (safety, tolerability of multiple subcutaneous dosings in PD patients)
- Prepare for Phase 2 readiness
- Explore HER-096 in other indications

Strategy

Find a development partner for HER-096

Thank you!

Contact details:
CEO Antti Vuolanto, antti.vuolanto@herantis.com
CFO Tone Kvåle, tone.kvale@herantis.com